Similar articles

• Oral BG-12 in multiple sclerosis.

  Fox RJ, Havrdova E. Fox RJ, et al. N Engl J Med. 2013 Apr 25;368(17):1652-3. doi: 10.1056/NEJMc1212740. N Engl J Med. 2013. PMID: 23614593 No abstract available.
• Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM. Evaluation of: Gold R, Kappos L, Arnold D, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-107; and Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97.

  Havrdova E, Hutchinson M, Kurukulasuriya NC, Raghupathi K, Sweetser MT, Dawson KT, Gold R. Havrdova E, et al. Expert Opin Pharmacother. 2013 Oct;14(15):2145-56. doi: 10.1517/14656566.2013.826190. Epub 2013 Aug 24. Expert Opin Pharmacother. 2013. PMID: 23971970
• The best clinical paper on multiple sclerosis in 2012.

  Miller AE. Miller AE. Mult Scler. 2013 Apr;19(5):520-1. doi: 10.1177/1352458513482386. Mult Scler. 2013. PMID: 23599182 No abstract available.
• The fumaric acid ester BG-12: a new option in MS therapy.

  Lee DH, Stangel M, Gold R, Linker RA. Lee DH, et al. Expert Rev Neurother. 2013 Aug;13(8):951-8. doi: 10.1586/14737175.2013.814958. Epub 2013 Aug 14. Expert Rev Neurother. 2013. PMID: 23944289 Review.
• Dimethyl fumarate (BG-12) for the treatment of multiple sclerosis.

  Stangel M, Linker RA. Stangel M, et al. Expert Rev Clin Pharmacol. 2013 Jul;6(4):355-62. doi: 10.1586/17512433.2013.811826. Expert Rev Clin Pharmacol. 2013. PMID: 23927662 Review.